RTW Biotech Opportunities (LSE:RTW) 1-Year Sharpe Ratio: 2.82 (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
40 GF Score
Price $2.51
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities 1-Year Sharpe Ratio?

RTW Biotech Opportunities LSE:RTW +0.80% 40 1-Year Sharpe Ratio is 2.82 as of Aug. 09, 2026. GuruFocus rates LSE:RTW with a GF Score™ of 40/100. The stock has 2 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-09), RTW Biotech Opportunities's 1-Year Sharpe Ratio is 2.82.

RTW Biotech Opportunities  (LSE:RTW) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

RTW Biotech Opportunities 1-Year Sharpe Ratio Related Terms

LSE:RTW vs BLK, BX, KKR: 1-Year Sharpe Ratio Comparison

For the Asset Management subindustry, RTW Biotech Opportunities's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RTW Biotech Opportunities 1-Year Sharpe Ratio vs Asset Management Industry

For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where RTW Biotech Opportunities's 1-Year Sharpe Ratio falls into.


LSE:RTW
40GF Score
RTW Biotech Opportunities Ltd LSE:RTW
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 2.82 mean?
RTW Biotech Opportunities (LSE:RTW) has a 1-Year Sharpe Ratio of 2.82 as of Aug. 09, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' 1-Year Sharpe Ratio too high?
RTW Biotech Opportunities' current 1-Year Sharpe Ratio is 2.82. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' 1-Year Sharpe Ratio compare to BLK and BX?
RTW Biotech Opportunities' 1-Year Sharpe Ratio of 2.82 can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for an Asset Management company?
A good 1-Year Sharpe Ratio depends on the Asset Management industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current 1-Year Sharpe Ratio is 2.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current 1-Year Sharpe Ratio of 2.82. The current 1-Year Sharpe Ratio is 2.82. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current 1-Year Sharpe Ratio is 2.82 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score

Get the complete analysis for LSE:RTW

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.51
Price